Vaxcyte (MIL:1PCVX) Other Current Liabilities: €6.91 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1PCVX Vaxcyte Inc MIL:1PCVX
11 GF Score
Price €50.00
! 3 Warning Signs
View Full Analysis

What is Vaxcyte Other Current Liabilities?

Vaxcyte MIL:1PCVX 11 Other Current Liabilities is €6.91 Mil as of Mar. 2026. GuruFocus rates MIL:1PCVX with a GF Score™ of 11/100. The stock has 3 warning signs investors should review.

Vaxcyte's other current liabilities for the quarter that ended in Mar. 2026 was €6.91 Mil.

Vaxcyte's quarterly other current liabilities increased from Sep. 2025 (€14.28 Mil) to Dec. 2025 (€19.64 Mil) but then declined from Dec. 2025 (€19.64 Mil) to Mar. 2026 (€6.91 Mil).

Vaxcyte's annual other current liabilities increased from Dec. 2023 (€10.14 Mil) to Dec. 2024 (€19.63 Mil) and increased from Dec. 2024 (€19.63 Mil) to Dec. 2025 (€19.64 Mil).

Vaxcyte Other Current Liabilities Related Terms

Vaxcyte Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Vaxcyte's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaxcyte Other Current Liabilities Chart

Vaxcyte Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial 3.06 1.11 10.14 19.63 19.64

Vaxcyte Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.54 9.39 14.28 19.64 6.91
MIL:1PCVX
11GF Score
Vaxcyte Inc MIL:1PCVX
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vaxcyte Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €6.91 Mil mean?
Vaxcyte (MIL:1PCVX) has a Other Current Liabilities of €6.91 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Vaxcyte.
Is Vaxcyte's Other Current Liabilities too high?
Vaxcyte's current Other Current Liabilities is €6.91 Mil. Overall, Vaxcyte has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Vaxcyte's Other Current Liabilities compare to IMVT and PTGX?
Vaxcyte's Other Current Liabilities of €6.91 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Vaxcyte. Vaxcyte's current Other Current Liabilities is €6.91 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxcyte stock overvalued right now?
Vaxcyte (MIL:1PCVX) has a current Other Current Liabilities of €6.91 Mil. The current Other Current Liabilities is €6.91 Mil. Vaxcyte's overall GF Score™ is 11/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Vaxcyte (MIL:1PCVX), the current Other Current Liabilities is €6.91 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vaxcyte Business Description

Other Exchanges PCVX:USA5VA:Germany
Address 825 Industrial Road, Suite 300, San Carlos, CA, USA, 94070
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
11GF Score

Get the complete analysis for MIL:1PCVX

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€50.00
Price